US5599352A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of making a drug eluting stent
Assignee: Medtronic Inc
•
Filing: 1994-09-15
•
Granted: 1997-02-04
•
Expires: 2014-09-15
Abstract
Abstract An intraluminal stent comprising fibrin and an elutable drug is capable of providing a treatment of restenosis.
Inventors
- 👤 Thomas Q. Dinh
- 👤 Ronald J. Tuch
- 👤 Robert S. Schwartz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:13
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/82; A61L; A61L31/00; A61L31/04; A61L31/041; A61L31/043; A61L31/046; A61L31/047; A61L31/08; A61L31/10; A61L31/12; A61L31/125; A61L31/128; A61L31/14; A61L31/16; A61F2/0077; A61F2240/00; A61F2240/001; A61F2250/00; A61F2250/0058; A61F2250/0067; A61L2300/00; A61L2300/20; A61L2300/252; A61L2300/40; A61L2300/416; A61L2300/60; A61L2300/606; A61L2420/00; A61L2420/08; B; B05; B05C; B05C3/00; B05C3/20; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/921
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
53 words
A method for making a drug eluting intravascular stent comprising the steps of: (a) providing a generally cylindrical stent body; (b) applying to the stent body a first layer which is a solid composite of polymer and therapeutic substance; and (c) applying as a second layer a layer of fibrin over the composite.
Claim 2
Independent Claim
53 words
A method for making a drug eluting intravascular stent comprising the steps of: (a) providing a generally cylindrical stent body; (b) applying to the stent body a first layer which is a solid composite of polymer and therapeutic substance; and (c) applying as a second layer a layer of fibrin over the composite.
Claim 3
Dependent Claim
55 words
The method of claim 1 wherein the first layer is applied by the steps of: (a) applying to the stent body a solution which includes a solvent, a polymer dissolved in the solvent and a therapeutic substance dispersed in the solvent; and (b) evaporating the solvent to form a composite of polymer and therapeutic substance.
Claim 4
Dependent Claim
13 words
A method according to claim 2 wherein the solution is applied by spraying.
Claim 5
Dependent Claim
19 words
A method according to claim 2 wherein the solution is applied in a plurality of application and drying steps.
Claim 6
Dependent Claim
28 words
A method according to claim 2 wherein the ratio of therapeutic substance to dissolved polymer in the solution is varied in some of the plurality of application steps.
Claim 7
Dependent Claim
13 words
A method according to claim 2 wherein the polymer is a bioabsorbable polymer.
Claim 8
Dependent Claim
21 words
A method according to claim 6 wherein the polymer is selected from the group consisting of poly(L-lactic acid), poly(lactide-co-glycolide) and poly(hydroxybutyrate-co-valerate).
Claim 9
Dependent Claim
13 words
A method according to claim 2 wherein the polymer is a biostable polymer.
Claim 10
Dependent Claim
30 words
A method according to claim 8 wherein the polymer is selected from the group consisting of silicones, polyurethanes, polyesters, vinyl homopolymers and copolymers, acrylate homopolymers and copolymers, polyethers and cellulosics.
Claim 11
Dependent Claim
56 words
The method of claim 1 wherein the first layer is applied by the steps of: (a) applying to the stent body a solution which includes fibrinogen; (b) applying thrombin to the fibrinogen on the stent body to effect polymerization of the fibrinogen; and (c) applying a therapeutic substance to the fibrinogen as the fibrinogen is polymerizing.
Claim 12
Dependent Claim
48 words
The method of claim 1 wherein the first layer is applied by the steps of: (a) applying to the stent body a solution which includes fibrinogen and a dispersed therapeutic substance; and (b) applying thrombin to the fibrinogen on the stent body to effect polymerization of the fibrinogen.
Claim 13
Dependent Claim
40 words
A method according to claim 1 wherein the therapeutic substance is selected from the group consisting of glucocorticoids, heparin, hirudin, tocopherol, angiopeptin, aspirin, ACE inhibitors, growth factors, oligonucleotides, antiplatelet agents, anticoagulant agents, antimitotic agents, antioxidants, antimetabolite agents, and anti-inflammatory agents.
Claim 14
Dependent Claim
23 words
A method according to claim 1 wherein the fibrin is applied by molding a polymerization mixture of fibrinogen and thrombin onto the composite.
References Cited (Backward Citations)
US3523807A
Cited
US4622244A
Cited
US4464317A
Cited
US4389330A
Cited
US4675189A
Cited
US4530840A
Cited
US4542025A
Cited
US4540573A
Cited
US4548736A
Cited
EP0166263A1
Cited
US5223420A
Cited
US4600652A
Cited
US4642242A
Cited
US5116962A
Cited
US4720512A
Cited
US4943449A
Cited
US4897268A
Cited
US4886062A
Cited
US5019096A
Cited
EP0649637A1
Cited
EP0364787B1
Cited
EP0366564A2
Cited
WO1990013332A1
Cited
US5141516A
Cited
EP0420541A2
Cited
WO1991012779A1
Cited
US5092841A
Cited
WO1991017789A1
Cited
US5246451A
Cited
WO1992022312A1
Cited
EP0566245A1
Cited
EP0604022A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-04 | 2000-08-05 | 2001-02-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-04 | 2004-08-05 | 2005-02-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-04 | 2008-08-05 | 2009-02-04 | $7700.00 | Window Closed / Lapsed |